Teva Pharmaceutical (TEVA) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Teva Pharmaceutical (TEVA)

38.33

+1.24 (3.34%)

as of Sep 14, 2026, 7:59:59 pm Market Open.

70 watching

Investor Insights

Sep 14, 2026, 12:00 am

This summary was created by AI, based on 5 opinions in the last 12 months.

Teva Pharmaceutical is experiencing a turnaround under its current CEO, with a significant 264% increase since January 2023. The company's growth strategy is yielding positive results, which has recently led to an upgrade in its credit rating by Moody's to investment grade. Factors contributing to this positive outlook include a diverse revenue stream, improving operating margins, strong free cash flow, and an expanding pipeline of innovative products. Despite facing challenges in the generic drug market and criticism about its innovation, expert opinions suggest that Teva remains a strong candidate within the healthcare sector, bolstered by solid cash reserves and expectations for further debt reduction. Analysts project a positive price trajectory for the stock, indicating growth potential over the coming months.

Consensus

Positive

Valuation

Undervalued

Similar

Novartis, NVS

Most recent Opinions go here

Be up to date, don't miss your chance.

TOP PICK

Stockchase Research Editor: Michael O'Reilly

Moody's just upgraded the credit rating to investment grade citing "the ongoing success of Teva’s growth strategy, including its key innovative products, an expanded pipeline and continued debt reduction supported by earnings growth. Moody’s also noted Teva’s revenue diversity, improving operating margins, solid free cash flow and ample cash on hand, as well as its expectation that Teva will further reduce debt over the next 12 to 18 months." Cash reserves are growing, while debt is reduced. We recommend setting a stop-loss at $30, looking to achieve $44 -- upside potential of 18%. Yield 0%

(Analysts’ price target is $42.38)

PAST TOP PICK

(A Top Pick Jan 08/26, Down 3%)

(Note the short timeframe.) Healthcare and drug sectors have been strong, so this should have done better. Reasonably high in the RSI index, it's OK, he still owns.

DON'T BUY

The demand of GLP remains strong, but as more generics enter the market, the prices of the GLPs will go down. If you bet on Teva, you expects GLP demand to remain strong. GLP will come in pill shape, and there will be more amazing drug discoveries. However, Teva isn't a very innovative company. He avoids pharma; it's too hard to determine who will be a winner.

BUY

After a rough patch after 2002, is up 264% under its current CEO since Jan. 2023. Today it reported good numbers. It's in a turnaround.

TOP PICK

HQ is in Israel. Large-cap pharma. Right now, #1-ranked in his ADR/CDR universe (international stocks with American/Canadian Depositary Receipts). We've seen rotation into drug stocks. Broke out over $21 in September and has kept right on going. Very strong accumulation for about 6 months now. No dividend.

(Analysts’ price target is $34.50)

DON'T BUY

It's cheap and has momentum, but that's all it has now. It never grabbed him.

DON'T BUY

Massive share price appreciation not sustainable.
Large debt load presents difficulties.
Does not own shares.
Would not recommend buying at this time.

BUY ON WEAKNESS

Has owned company for a long period of time in the past. Previous reasons for owning stock not present anymore. Waiting to see if new drugs are invented/patented.

Wealthica Track your Stocks in your Watch List

DON'T BUY

He's put the white flag up on this one. It's about macro interest rates, currency moves. Don't waste your time with these story stocks. His model price is $18.80, and it could have all the fundamentals, but the macro waves swamp the boat. Go with the big names.

DON'T BUY

Tends to avoid companies with a ton of debt. Management missteps, and investors are paying for those. In the depths of a tough turnaround. He'd rather own a VTRS, where the debt is manageable, balance sheet's in better shape, with a better growth trajectory.

DON'T BUY

Involved in the opiate crisis. Balance sheet is weak. Overall topline growth is low. Stay away. A lot of problems still to overcome.

DON'T BUY

Doesn't offer growth. The stock is weak and will stay weak.

BUY

It's time to get back in. They all went crazy and then slid on sympathy when valiant went bust. There is tremendous value here. His model price is $21.26 or 63% upside. They presented earnings and the balance sheet looks great.

HOLD

Generic brand companies like Teva have struggled in the last 5 years has they competed with each others. Pfizer is in the process of buying one of their competitors and the Pfizer stock dropped 5$ on the announcement. Doesn't own Teva, purchased United Heatlth recently. You can hold but it's not a name he would hold due to the risk and they have no value added.

DON'T BUY

They went from an in incredibly well managed drug company and then management decided to develop their own drugs and make mistakes. It is difficult to unwind these problems. Turning around a company like this will be difficult because of the debt. This is a highly speculative stock.

Showing 1 to 15 of 277 entries

Most Recent Experts

Ryan Bushell

Newhaven Asset Management

Liz Young, Head of investment strategy at SoFi

SoFi

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Jim Lebenthal

Cerity Partners

Joe Terranova

Virtus Investment Partners

Teva Pharmaceutical (TEVA) Frequently Asked Questions

What is Teva Pharmaceutical stock symbol?

Teva Pharmaceutical is a American stock, trading under the symbol TEVA (previously TEVA-N on Stockchase) on the New York Stock Exchange (TEVA). It is usually referred to as NYSE:TEVA or TEVA

Is Teva Pharmaceutical a buy or a sell?

In the last year, 5 stock analysts issued a Buy, Sell, or Hold rating on TEVA (previously TEVA-N on Stockchase). 4 analysts recommended to BUY and 1 analyst recommended to SELL the stock. The latest stock analyst rating is TOP PICK. Read the latest stock experts' ratings for Teva Pharmaceutical.

Is Teva Pharmaceutical a good investment or a top pick?

Teva Pharmaceutical was recommended as a Top Pick by The Panic-Proof Portfolio (Stockchase Research) on 2026-08-20. Read the latest stock experts ratings for Teva Pharmaceutical.

Why is Teva Pharmaceutical stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Teva Pharmaceutical.

Is Teva Pharmaceutical worth watching?

Teva Pharmaceutical is followed by 70 investors on Stockchase and is a trending stock that is worth watching.

What is Teva Pharmaceutical stock price?

On 2026-09-14, Teva Pharmaceutical (TEVA) stock closed at a price of $38.33.

4.2(5)

Based on 5 expert opinions: 4 buy 0 hold 1 sell

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Teva Pharmaceutical (TEVA)

Most recent Opinions go here